Some vaccines have trace levels of thimerosal left over from the manufacturing process (less than 1 µg thimerosal per 0.5 mL dose of vaccine), [25] an amount that is considered insignificant.

During the height of the initial mpox outbreak in 2022, the Jynneos vaccine was in short supply and a lower 0.1 mL intradermal dose was recommended to preserve vaccine availability. However ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

[6] Table 3. GMTs of Anti-HBs After Boosting With 1 Dose of RecombivaxHB Vaccine Among Children with Anti-HBs <10 mIU/mL ...